Downstream Processing Industry News
-
FDA Approves GlaxoSmithKline's Four-Strain Seasonal Influenza Vaccine For Use In The U.S.
12/17/2012
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX® QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
-
Janssen Research & Development Submits New Drug Application To U.S. FDA For Canagliflozin/Metformin Fixed-Dose Combination Therapy To Treat Patients With Type 2 Diabetes
12/12/2012
Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes.
-
Amarantus BioSciences Announces Positive Data For MANF In Delivery Diffusion Animal Model Of Parkinson's Disease
11/27/2012
Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.
-
Five New Cases Of SARS-Like Virus Bring Total To Seven, Prompting Calls For Immediate Trials Of New Synthetic Replikin™ Vaccine SARS 2012
11/27/2012
The World Health Organization (WHO) last week reported that four new cases of SARS-like virus have been found in Saudi Arabia and Qatar, and the Department of Health in Singapore reported one additional case, adding to the two cases from the Middle East reported in late September.
-
TauRx Pharmaceuticals Receives $111.8M Commitment From Genting To Prepare For Market Leadership In Alzheimer's
11/20/2012
TauRx Pharmaceuticals Ltd. ("TauRx") announced today the receipt of a further equity investment of US$31.5m from Genting Management (Singapore) Pte. Ltd. ("GMS"), a wholly owned subsidiary of Genting Berhad.
-
Cell Culture - Rising Demand For Biologics And Growing Visibility Of Approval Pathway For Biosimilars Will Create Growth Opportunities
11/19/2012
GBI Research, the leading business intelligence provider, has released its latest research "Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities", which provides in-depth analysis on the processes, drivers and barriers of the cell culture market.
-
ClinicalRM Awarded Contract For Regulatory, Clinical And Technical Services To Support The U.S. Army Medical Materiel Development Activity (USAMMDA)
11/15/2012
Clinical Research Management, Inc. (ClinicalRM), a full-service Contract Research Organization providing services for basic and applied research, clinical trials, and regulatory support, announced today it was awarded a USAMMDA contract.
-
Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (TMC435) And VX-135 For Treatment Of Hepatitis C
11/1/2012
Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).
-
Amarantus BioSciences Announces MANF Demonstrates Superiority Over GDNF In Neurorestoration Behavioural Animal Model Of Parkinson's Disease
10/25/2012
Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease.
-
Sigma® Life Science Launches Novel, Affordable Pluripotent Stem Cell Culture Medium
10/15/2012
Sigma-Aldrich® Corp. announced that Sigma Life Science, its innovative biological products and services research business, has launched Stemline® Pluripotent Culture Medium, a novel human pluripotent stem cell culture medium that provides a consistent environment for the long-term maintenance and growth of healthy pluripotent stem cells.